Just the other day we noted that among the issues Dexcom wannabes must navigate is the treacherous minefield known as IP. Well this minefield just became more treacherous, per a Dexcom press release;
“The U.S. District Court for the District of Oregon has granted Dexcom's (NASDAQ:DXCM) motion for summary judgment invalidating all asserted claims in the two remaining patents asserted against it by WaveForm Technologies, Inc., a subsidiary of AgaMatrix.”
With this litigation now behind them Dexcom like everyone else is waiting to see whether or not the FDA will grant the Libre2 an iCGM designation.
This content is restricted to subscribers. Please subscribe. Already have an account? Please login.
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.